FibroBiologics has initiated a Phase 1/2 trial of CYWC628, a fibroblast-spheroid cell therapy applied topically to diabetic foot ulcers, enrolling up to 120 patients across Australian sites. The study will assess safety, tolerability, and efficacy compared with standard care alone, with interim analysis at six weeks to evaluate wound healing and safety endpoints.
Key Points
- Topical fibroblast-spheroid cell therapy entering human trials for diabetic foot ulcers
- Multicenter randomized design comparing low dose, high dose, and standard care alone
- Preclinical data suggest acceleration of wound healing; interim analysis at six weeks
Longevity Analysis
Diabetic foot ulcers represent a critical failure point in metabolic and vascular health — they signal dysregulation in glucose metabolism, impaired circulation, and compromised regenerative capacity. A cell-based approach to accelerating wound healing addresses not just the wound itself but the underlying inability of tissues to respond appropriately to injury. Success in this trial would demonstrate that exogenous cellular signals can restore regenerative competence in tissues chronically exposed to hyperglycemia, offering a model for how tissue-level dysfunction in aging and metabolic disease can be targeted at the source rather than merely managed symptomatically.
Original published by Longevity.Technology.